|
Schirdewan博士的引述的參考文獻:
% ?/ C, U3 z8 ~& t3 p% {7 v
# t# t/ L+ g0 { o) O- XCamm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009.
" q4 L5 f) v/ v& B F+ ?+ N! Z2 f& T2 R( F8 t& o' Z. f; T
Daubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008
% Q3 E7 o. i; o1 S
6 X1 F5 F! {1 o# U0 N0 m s# uRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010.
1 u& [: ~3 }% l4 |
( O9 V6 u2 s0 z5 c2 p8 s2 P, L' H關於BIOTRONIK SE & Co. KG
7 \9 c4 k# e5 n+ W
1 n/ e7 x8 j# l8 P3 I$ P% _2 V. gBIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|